Sativex effective in alleviating pain and allodynia from neuropathy after 5-week follow up
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trialPain. 2007 Dec 15;133(1-3):210-20
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
125 patients experiencing unilateral peripheral neuropathic pain and allodynia were randomly assigned to either treatment with sativex, a delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) endocannabinoid system modulator, or placebo. Patient-reported pain and allodynia severity, as well as the incidence of adverse events, were assessed at baseline and 5-week follow up. Results demonstrated th...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue